JP2017537896A - 二重特異性抗体及び眼科に使用する方法 - Google Patents

二重特異性抗体及び眼科に使用する方法 Download PDF

Info

Publication number
JP2017537896A
JP2017537896A JP2017525022A JP2017525022A JP2017537896A JP 2017537896 A JP2017537896 A JP 2017537896A JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017537896 A JP2017537896 A JP 2017537896A
Authority
JP
Japan
Prior art keywords
amino acid
hvr
seq
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017525022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537896A5 (enExample
Inventor
ベドゥーシャ，マルク
ブロイアー，セバスティアン
デングル，シュテファン
ガスナー，クリスティアン
ジョルジュ，ギー
グリューナー，ザビーネ
ハルトマン，グイド
ヒュールスマン，ペーター・ミヒャエル
ケッテンベルガー，フーベルト
モルケン，イェルク
モルホイ，ミヒャエル
ムンディグル，オラフ
レグラ，イェルク・トーマス
シューマッハー，ラルフ
ヴァイザー，バルバラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2017537896A publication Critical patent/JP2017537896A/ja
Publication of JP2017537896A5 publication Critical patent/JP2017537896A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017525022A 2014-11-10 2015-11-06 二重特異性抗体及び眼科に使用する方法 Pending JP2017537896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192517 2014-11-10
EP14192517.2 2014-11-10
PCT/EP2015/075879 WO2016075037A1 (en) 2014-11-10 2015-11-06 Bispecific antibodies and methods of use in ophthalmology

Publications (2)

Publication Number Publication Date
JP2017537896A true JP2017537896A (ja) 2017-12-21
JP2017537896A5 JP2017537896A5 (enExample) 2018-12-06

Family

ID=51868112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525022A Pending JP2017537896A (ja) 2014-11-10 2015-11-06 二重特異性抗体及び眼科に使用する方法

Country Status (15)

Country Link
US (1) US10730938B2 (enExample)
EP (1) EP3218399A1 (enExample)
JP (1) JP2017537896A (enExample)
KR (1) KR20170080584A (enExample)
CN (1) CN107074941A (enExample)
AR (1) AR102592A1 (enExample)
AU (1) AU2015345323A1 (enExample)
BR (1) BR112017009764A2 (enExample)
CA (1) CA2963175A1 (enExample)
IL (1) IL251128A0 (enExample)
MX (1) MX2017005977A (enExample)
RU (1) RU2017120360A (enExample)
SG (1) SG11201703428SA (enExample)
TW (1) TW201632551A (enExample)
WO (1) WO2016075037A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520414A (ja) * 2020-03-30 2023-05-17 エフ． ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3218398A1 (en) * 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-ang2 antibodies and methods of use
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
BR112017009792A2 (pt) 2014-11-10 2018-02-27 Hoffmann La Roche anticorpos anti-pdgf-b e métodos de uso
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3034574A1 (en) * 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a and anti-ang2 antibodies and uses thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN119708249A (zh) * 2018-12-21 2025-03-28 豪夫迈·罗氏有限公司 与VEGF和IL-1β结合的抗体及其使用方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2023014407A (es) * 2021-06-04 2024-04-23 Innovent Biologics Suzhou Co Ltd Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma.
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025211874A1 (ko) * 2024-04-04 2025-10-09 주식회사 크로스포인트테라퓨틱스 인간 항체 fc 변이체 포함 이중항체 및 그 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526485A (ja) * 2010-05-07 2013-06-24 ゾーマ テクノロジー リミテッド ＩＬ−１β関連病態の治療のための方法
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014072876A1 (en) * 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003073982A2 (en) 2002-02-28 2003-09-12 Eli Lilly And Company Anti-interleukin-1 beta analogs
CA2492092A1 (en) 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2004067568A2 (en) 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists
NZ541657A (en) 2003-01-28 2009-01-31 Academisch Ziekenhuis Leiden Peptide inhibitors of toxins derived from LL-37
US20050226863A1 (en) 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
SI1838733T1 (sl) 2004-12-21 2011-12-30 Medimmune Ltd Protitelesa usmerjena na angiopoietin-2 in njih uporaba
CN101217979A (zh) 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
HRP20130042T1 (hr) 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR20110110349A (ko) 2009-01-29 2011-10-06 아보트 러보러터리즈 Ｉｌ-1 결합 단백질
MX2012004412A (es) 2009-10-15 2012-05-08 Abbott Lab Proteinas de union a il-1.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
BR112013015944A2 (pt) 2010-12-21 2018-06-19 Abbvie Inc imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
AU2012229048B2 (en) 2011-03-16 2016-01-21 Amgen Inc Fc variants
JP6069312B2 (ja) 2011-06-29 2017-02-01 アムジェン インコーポレイテッド 腎細胞癌の治療における生存の予測バイオマーカー
KR20150023957A (ko) * 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
WO2014049100A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
CA2883807A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
CN105143262A (zh) * 2013-04-29 2015-12-09 豪夫迈·罗氏有限公司 结合人fcrn的修饰的抗体和使用方法
PE20160753A1 (es) 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
BR112017009792A2 (pt) 2014-11-10 2018-02-27 Hoffmann La Roche anticorpos anti-pdgf-b e métodos de uso
EP3218398A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-ang2 antibodies and methods of use
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
MX2019014199A (es) 2017-06-02 2020-01-23 Boehringer Ingelheim Int Tratamiento de combinacion antineoplasico.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526485A (ja) * 2010-05-07 2013-06-24 ゾーマ テクノロジー リミテッド ＩＬ−１β関連病態の治療のための方法
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014072876A1 (en) * 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520414A (ja) * 2020-03-30 2023-05-17 エフ． ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法

Also Published As

Publication number Publication date
EP3218399A1 (en) 2017-09-20
WO2016075037A1 (en) 2016-05-19
CN107074941A (zh) 2017-08-18
AR102592A1 (es) 2017-03-08
KR20170080584A (ko) 2017-07-10
MX2017005977A (es) 2017-06-29
BR112017009764A2 (pt) 2018-02-20
AU2015345323A1 (en) 2017-04-06
US20170240629A1 (en) 2017-08-24
TW201632551A (zh) 2016-09-16
US10730938B2 (en) 2020-08-04
RU2017120360A (ru) 2018-12-13
SG11201703428SA (en) 2017-05-30
RU2017120360A3 (enExample) 2019-10-18
CA2963175A1 (en) 2016-05-19
IL251128A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
US10730938B2 (en) Bispecific antibodies and methods of use in ophthalmology
US10344085B2 (en) Anti-IL-1beta antibodies
US10087246B2 (en) Anti-PDGF-B antibodies and methods of use
AU2016333511B2 (en) Humanized anti-human CD19 antibodies and methods of use
JP7436365B2 (ja) 抗ｖｅｇｆ抗体及び使用の方法
HK1236207A1 (en) Bispecific antibodies and methods of use in ophthalmology
HK1239711A1 (en) Anti-pdgf-b antibodies and methods of use
HK1238257A1 (en) Anti-il-1beta antibodies and methods of use
HK1239711B (zh) 抗-pdgf-b抗体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201006